PMID- 32283569
OWN - NLM
STAT- MEDLINE
DCOM- 20210430
LR  - 20210430
IS  - 1582-4934 (Electronic)
IS  - 1582-1838 (Print)
IS  - 1582-1838 (Linking)
VI  - 24
IP  - 10
DP  - 2020 May
TI  - Mesenchymal stem cells alleviate rat diabetic nephropathy by suppressing CD103(+) 
      DCs-mediated CD8(+) T cell responses.
PG  - 5817-5831
LID - 10.1111/jcmm.15250 [doi]
AB  - Diabetic nephropathy (DN) as a kind of serious microvascular complication of 
      Diabetes Mellitus (DM) usually causes the end-stage of renal disease (ESRD). 
      Studies have demonstrated that CD103(+) dendritic cells (DCs) exhibited a renal 
      pathogenic effect in murine chronic kidney disease (CKD). Mesenchymal stem cells 
      (MSCs) can alleviate DN and suppress the DCs maturation. To explore the role of 
      CD103(+) DCs and the potential mechanisms underlying MSCs-mediated protective 
      effects in DN, we used bone marrow MSCs (BM-MSCs) to treat DN rats. MSCs 
      transplantation considerably recovered kidney function and diminished renal 
      injury, fibrosis and the population of renal CD103(+) DCs in DN rat. The 
      MSCs-treated DN rats had decreased mRNA expression levels of interleukin (IL)1beta, 
      IL6, tumour necrosis factor alpha (TNF-alpha), monocyte chemotactic protein 1 (MCP-1) 
      and reduced CD8 T cell infiltration in the kidney. MSCs significantly 
      down-regulated the genes expression of transcription factors (Basic leucine 
      zipper transcriptional factor ATF-like 3, Batf3 and DNA-binding protein inhibitor 
      ID-2, Id2) and FMS-like tyrosine kinase-3 (Flt3) which are necessary for CD103(+) 
      DCs development. The protective effect of MSCs may be partly related to their 
      immunosuppression of CD8(+) T cell proliferation and activation mediated by 
      CD103(+) DCs in the kidney of DN rats.
CI  - (c) 2020 The Authors. Journal of Cellular and Molecular Medicine published by 
      Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
FAU - Zhang, Fuping
AU  - Zhang F
AUID- ORCID: 0000-0003-2199-4609
AD  - Key Laboratory of Transplant Engineering and Immunology, Regenerative Medicine 
      Research Center, West China Hospital, Sichuan University, Chengdu, China.
FAU - Wang, Chengshi
AU  - Wang C
AUID- ORCID: 0000-0002-0650-4109
AD  - Key Laboratory of Transplant Engineering and Immunology, Regenerative Medicine 
      Research Center, West China Hospital, Sichuan University, Chengdu, China.
FAU - Wen, Xin
AU  - Wen X
AD  - Key Laboratory of Transplant Engineering and Immunology, Regenerative Medicine 
      Research Center, West China Hospital, Sichuan University, Chengdu, China.
FAU - Chen, Yang
AU  - Chen Y
AD  - Key Laboratory of Transplant Engineering and Immunology, Regenerative Medicine 
      Research Center, West China Hospital, Sichuan University, Chengdu, China.
FAU - Mao, Ruiwen
AU  - Mao R
AD  - Key Laboratory of Transplant Engineering and Immunology, Regenerative Medicine 
      Research Center, West China Hospital, Sichuan University, Chengdu, China.
FAU - Cui, Danli
AU  - Cui D
AD  - Key Laboratory of Transplant Engineering and Immunology, Regenerative Medicine 
      Research Center, West China Hospital, Sichuan University, Chengdu, China.
FAU - Li, Lan
AU  - Li L
AD  - Key Laboratory of Transplant Engineering and Immunology, Regenerative Medicine 
      Research Center, West China Hospital, Sichuan University, Chengdu, China.
FAU - Liu, Jingping
AU  - Liu J
AUID- ORCID: 0000-0001-8364-639X
AD  - Key Laboratory of Transplant Engineering and Immunology, Regenerative Medicine 
      Research Center, West China Hospital, Sichuan University, Chengdu, China.
FAU - Chen, Younan
AU  - Chen Y
AD  - Key Laboratory of Transplant Engineering and Immunology, Regenerative Medicine 
      Research Center, West China Hospital, Sichuan University, Chengdu, China.
FAU - Cheng, Jingqiu
AU  - Cheng J
AD  - Key Laboratory of Transplant Engineering and Immunology, Regenerative Medicine 
      Research Center, West China Hospital, Sichuan University, Chengdu, China.
FAU - Lu, Yanrong
AU  - Lu Y
AUID- ORCID: 0000-0002-3728-222X
AD  - Key Laboratory of Transplant Engineering and Immunology, Regenerative Medicine 
      Research Center, West China Hospital, Sichuan University, Chengdu, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200413
PL  - England
TA  - J Cell Mol Med
JT  - Journal of cellular and molecular medicine
JID - 101083777
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, Differentiation, Myelomonocytic)
RN  - 0 (CD68 antigen, human)
RN  - 0 (Integrin alpha Chains)
RN  - 0 (alpha E integrins)
SB  - IM
MH  - Animals
MH  - Antigens, CD/*metabolism
MH  - Antigens, Differentiation, Myelomonocytic/metabolism
MH  - CD8-Positive T-Lymphocytes/*immunology
MH  - Cell Proliferation
MH  - Cytotoxicity, Immunologic
MH  - Dendritic Cells/*metabolism
MH  - Diabetic Nephropathies/*immunology/pathology/*therapy
MH  - Inflammation/pathology
MH  - Integrin alpha Chains/*metabolism
MH  - Kidney/injuries/pathology
MH  - Lymphocyte Activation/immunology
MH  - Macrophages/metabolism/pathology
MH  - Male
MH  - *Mesenchymal Stem Cell Transplantation
MH  - Mesenchymal Stem Cells/*metabolism
MH  - Models, Biological
MH  - Rats, Sprague-Dawley
PMC - PMC7214166
OTO - NOTNLM
OT  - CD103+ dendritic cells
OT  - diabetic nephropathy
OT  - immunosuppression
OT  - kidney injury
OT  - mesenchymal stem cells
COIS- The authors declared that there are no conflicts of interest.
EDAT- 2020/04/14 06:00
MHDA- 2021/05/01 06:00
PMCR- 2020/05/01
CRDT- 2020/04/14 06:00
PHST- 2019/12/23 00:00 [received]
PHST- 2020/02/27 00:00 [revised]
PHST- 2020/03/15 00:00 [accepted]
PHST- 2020/04/14 06:00 [pubmed]
PHST- 2021/05/01 06:00 [medline]
PHST- 2020/04/14 06:00 [entrez]
PHST- 2020/05/01 00:00 [pmc-release]
AID - JCMM15250 [pii]
AID - 10.1111/jcmm.15250 [doi]
PST - ppublish
SO  - J Cell Mol Med. 2020 May;24(10):5817-5831. doi: 10.1111/jcmm.15250. Epub 2020 Apr 
      13.